NeuroScientific Biopharmaceuticals (NSB) Q1 2026 TU earnings summary

Executive summary

• Patient recruitment for the Special Access Program in fistulising Crohn's disease advanced, with initial cohort approved by TGA post-quarter.

• Appointments of Dr Catherine Cole as Chief Medical Officer and Nathan Smith as CEO bring significant clinical and manufacturing expertise.

• Technology transfer to Q-Gen Cell Therapies commenced to scale StemSmart™ for clinical trials and commercialization.

• Historical studies support StemSmart™'s potential in renal transplantation, showing positive outcomes in graft retention and safety.

• EmtinB program progressed toward clinical readiness, focusing on formulation optimization and preclinical safety studies.

Financial highlights

• Cash balance stood at approximately A$6.9 million as of 30 September 2025.

• Net cash used in operating activities for the quarter was A$376k.

• Research and development payments were A$39k, staff costs A$138k, and administration/corporate costs A$477k for the quarter.

• Government grants and tax incentives received totaled A$318k.

• Estimated quarters of funding available is 18.32, indicating strong liquidity.

Outlook and guidance

• Special Access Program for Crohn's disease expected to complete by mid-CY2026, supporting initiation of Phase 2 clinical trial in CY2026.

• Results from the first four patients in the Special Access Program anticipated by end of CY2025.

• EmtinB program aims to finalize formulation and initiate pharmacokinetic studies, positioning for IND submission.